journal
MENU ▼
Read by QxMD icon Read
search

Clinical Neuropharmacology

journal
https://www.readbyqxmd.com/read/29194113/anger-assessment-in-patients-treated-with-brivaracetam
#1
Gemma Ortega, Laura Abraira, Glòria Martí, Manuel Quintana, Gonzalo Mazuela, Estevo Santamarina, Xavier Salas-Puig, Manuel Toledo
OBJECTIVES: To assess state and trait anger, adjusted by epilepsy type, seizure control, anxiety-depression status and quality of life, in patients treated with brivaracetam (BRV) from an open study. METHODS: We evaluated prospectively consecutive patients with partial onset seizures in an open-label study. Patients had 5 years or longer of epilepsy and were taking between 1 and 3 antiepileptic drugs. They were treated with BRV and compared with a control group selected from outpatients attending our epilepsy unit who met the following criteria: age ≥16 years and diagnosis of epilepsy with focal-onset seizures at least 1 year before inclusion in the study...
December 1, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29194112/drug-associated-spontaneous-orgasm-a-case-report-and-systematic-review-of-literature
#2
Wei-Hsi Chen, Yuan-Hsiang Chu, Kuo-Yen Chen
OBJECTIVES: Spontaneous orgasm is characterized by a spontaneous onset of orgasm without any preceding sexual or nonsexual trigger. It sheds insight on the mechanisms underlying orgasms and the sexual response cycle in humans. METHODS: We report a male patient of repetitive spontaneous orgasm under trazodone treatment and systematically review the literature on drug-associated spontaneous orgasm (DASO). RESULTS: A total of 25 patients (18 women and 7 men), including our reported case, experienced 27 DASO events...
December 1, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29194111/comment-on-selective-serotonin-reuptake-inhibitor-induced-hyponatremia-clinical-implications-and-therapeutic-alternatives
#3
Mehmet Ali Eren, Tevfik Sabuncu
No abstract text is available yet for this article.
December 1, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29194110/one-year-retention-study-of-adjunctive-perampanel-treatment-in-epilepsy-patients
#4
Dong Wook Kim, Jeeyoung Oh
OBJECTIVES: Perampanel is a recently introduced antiepileptic drug (AED) with a unique action mechanism of noncompetitive and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist. Because of delayed approval of perampanel in most Asian countries, there is limited information on the clinical usefulness of perampanel in the Asian population. We performed a retrospective analysis of retention rate, seizure outcome, and adverse events for perampanel treatment in South Korea...
December 1, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29059136/successful-use-of-escitalopram-for-the-treatment-of-visual-hallucinations-in-patients-with-parkinson-disease
#5
Joseph Bergman, Paul P Lerner, Shmuel Sokolik, Vladimir Lerner, Anatoly Kreinin, Chanoch Miodownik
INTRODUCTION: Patients with Parkinson disease (PD) frequently experience visual hallucinations (VH). Visual hallucinations are most often viewed as an adverse effect of antiparkinsonian treatment. Possible treatments for this disturbance include a reduction of antiparkinsonian medications, adding atypical antipsychotics, or cholinesterase inhibitors. Some studies demonstrated that selective serotonin reuptake inhibitors may be an optional treatment for patients experiencing psychosis or agitation in dementia...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29059135/pramipexole-and-electroconvulsive-therapy-in-treatment-resistant-depression
#6
Claire Gauthier, Lama Souaiby, Emmanuelle Advenier-Iakovlev, Raphaël Gaillard
BACKGROUND: Major depressive disorder (MDD) is a common disease. Despite appropriate antidepressant treatment, approximately one third of patients do not achieve adequate response. In these patients, electroconvulsive therapy (ECT) is a possible option. Nevertheless, some symptoms may persist even after ECT. METHOD: This is a comparative retrospective study assessing the efficacy and safety of pramipexole in the treatment of resistant depression, in combination to ECT or after a partial ECT efficacy...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29059134/aripiprazole-for-post-traumatic-stress-disorder-a-systematic-review
#7
Sara R Britnell, Anna D Jackson, Jamie N Brown, Bruce P Capehart
OBJECTIVE: The aim of this study was to review the safety and efficacy of aripiprazole as monotherapy and adjunct therapy for the treatment of post-traumatic stress disorder (PTSD). METHODS: A search of both MEDLINE (1956 to May 2017) and EMBASE (1957 to May 2017) was conducted using the terms "aripiprazole" and "post-traumatic stress disorder," "posttraumatic stress disorder," or "PTSD." Studies evaluating the primary endpoint of PTSD in patients taking aripiprazole as monotherapy or adjunct therapy were analyzed for relevance...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29059133/a-phase-ib-randomized-controlled-study-to-evaluate-the-effectiveness-of-a-single-dose-of-the-nr2b-selective-n-methyl-d-aspartate-antagonist-mk-0657-on-levodopa-induced-dyskinesias-and-motor-symptoms-in-patients-with-parkinson-disease
#8
W Joseph Herring, Christopher Assaid, Kerry Budd, Ryan Vargo, Ralph S Mazenko, Christopher Lines, Aaron Ellenbogen, Leo Verhagen Metman
OBJECTIVES: Blockade of N-methyl-D-aspartate receptors containing the NR2B subunit has been shown to be therapeutic in animal models of Parkinson disease (PD). However, findings with investigational NR2B receptor antagonists in PD patients have been mixed. The objective of this study was to evaluate the effects of the NR2B selective N-methyl-D-aspartate receptor antagonist MK-0657 on levodopa-induced dyskinesias and motor symptoms in PD patients. METHODS: A randomized, double-blind, single-dose, 2-period crossover study was conducted in 22 patients with PD and levodopa-induced peak-dose dyskinesias...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29059132/medical-cannabis-in-parkinson-disease-real-life-patients-experience
#9
Yacov Balash, Lihi Bar-Lev Schleider, Amos D Korczyn, Herzel Shabtai, Judith Knaani, Alina Rosenberg, Yehuda Baruch, Ruth Djaldetti, Nir Giladi, Tanya Gurevich
BACKGROUND: The use of medical cannabis (MC) is controversial. Support for its benefits is based on small clinical series. OBJECTIVE: The aim of this study was to report the results of a standardized interview study that retrospectively assessed the effects of MC on symptoms of Parkinson disease (PD) and its adverse effects in patients treated for at least 3 months. METHODS: The survey used telephone interviews using a structured questionnaire based on subjective global impressions of change for various parkinsonian symptoms and yes/no questions on adverse effects...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29045249/inhaled-loxapine-for-agitation-in-intoxicated-patients-a-case-series
#10
Carlos Roncero, Elena Ros-Cucurull, Raúl Felipe Palma-Álvarez, Alfonso Carlos Abad, Christian Fadeuilhe, Miquel Casas, Lara Grau-López
OBJECTIVES: Episodes of agitation are frequent in intoxicated patients who have a substance use disorder, a psychiatric disorder or both (dual diagnosis). For managing the agitation, it is necessary to act promptly in a safe environment and addressing any underlying etiology. Inhaled loxapine improves symptoms of agitation in adults with psychiatric disorders (eg, schizophrenia) within 10 minutes of administration. Recently, some reports have documented the usefulness of loxapine in dual diagnoses patients with agitation...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28976412/switch-from-originator-to-equivalent-drug-in-the-era-of-generic-antiepileptic-drugs-study-of-keppra-versus-epitiram-clinical-equivalence
#11
Martina Fanella, Alessandra Morano, Jinane Fattouch, Mariarita Albini, Luca M Basili, Sara Casciato, Mario Manfredi, Anna T Giallonardo, Carlo Di Bonaventura
OBJECTIVES: Generic antiepileptic drugs represent a measure to maximize cost saving. Levetiracetam (LEV) is one of most commonly used and effective antiepileptic drugs. The objective of our work was to demonstrate the effectiveness and safety of overnight switch from monotherapy with Keppra (original drug) to epitiram (generic drug) at the same dose. METHODS: In our observational study, we consecutively enrolled 37 seizure-free patients with epilepsy who expressed the wish to switch to a generic drug for economic reasons...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28976411/the-efficacy-of-istradefylline-for-treating-mild-wearing-off-in-parkinson-disease
#12
Ichiro Yabe, Mayumi Kitagawa, Ikuko Takahashi, Masaaki Matsushima, Hidenao Sasaki
OBJECTIVES: The adenosine A2A antagonist istradefylline has been used to treat Parkinson disease (PD) with symptoms of wearing-off since 2013 in Japan. Previous randomized controlled trials of istradefylline compared with placebo included PD patients experiencing an average daily OFF time of more than 2 hours. The purpose of this study is to assess the efficacy of 20 mg/d istradefylline in PD subjects experiencing an average daily OFF time of 3 hours or less. METHODS: Fifteen patients were enrolled into this retrospective study...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28976410/early-onset-schizophrenia-associated-with-obsessive-compulsive-disorder-clinical-features-and-correlates
#13
Burak Baytunca, Tuğba Kalyoncu, Ismail Ozel, Serpil Erermiş, Bülent Kayahan, Dost Öngur
OBJECTIVES: Obsessive-compulsive disorder (OCD) is notably a comorbid disorder in patients with schizophrenia. This study aimed to evaluate clinical features and correlates of early onset patients with schizophrenia with OCD. METHODS: In the present study, we included 10 patients with both schizophrenia and OCD and 19 patients with schizophrenia without OCD. The mean antipsychotic doses the patients needed for treatment are standardized as chlorpromazine equivalent dose...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28976409/subdural-instillation-of-a-thrombolytic-agent-for-treatment-of-recurrent-subdural-hematoma
#14
Mark B Frenkel, Aarti Sarwal, Mary Petrulis Wren, Christopher R Newey, Daniel E Couture
OBJECTIVE: This study aims to report the case of a patient with recurrent subdural hemorrhage (SDH) who was administered tissue plasminogen activator through a subdural drain to enhance drainage and prevent recurrence. METHODS: An 85-year-old man was treated for subacute over chronic SDH that kept on reaccumulating despite serial twist drill drainage, burr hole drainage, and craniotomy. No coagulopathy was identified with adequate blood pressure control. RESULTS: Treatment with tissue plasminogen activator resulted in successful drainage of the SDH, and the patient had no further recurrence at 9-month follow-up...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28976408/real-world-safety-and-patient-profile-of-fingolimod-in-relapsing-remitting-multiple-sclerosis-a-prospective-analysis-in-buenos-aires-argentina
#15
Juan Ignacio Rojas, Liliana Patrucco, Jimena Miguez, Edgardo Cristiano
OBJECTIVE: The aim was to evaluate fingolimod safety and patient profiles in a real-world setting in Buenos Aires, Argentina. METHODS: Relapsing-remitting patients with multiple sclerosis who had been prescribed fingolimod and at least 18 months or more of follow-up were included. Demographic, clinical, and safety issues were described during first dose and follow-up. RESULTS: A total of 145 patients were included, 68% female; mean age, 30 ± 10...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28922290/effectiveness-of-low-dose-aripiprazole-monotherapy-in-the-treatment-for-an-adolescent-with-obsessive-compulsive-disorder
#16
Merve Sertdemir, Ömer Faruk Akça
No abstract text is available yet for this article.
September 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28922289/letter-to-the-editor-about-efficacy-of-treatments-for-infantile-spasms-a-systematic-review
#17
Shahabeddin Rezaei, Ahmed Abdulahi Abdurahman, Maryam Mahmoudi
No abstract text is available yet for this article.
September 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28922288/addition-of-filgrastim-neupogen-for-clozapine-rechallenge-in-the-case-of-parkinson-disease-patient
#18
Joseph Friedman, Edith Yeboah, Matthew Hermenau
No abstract text is available yet for this article.
September 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28922287/pregabalin-toxicity-manifesting-as-reversible-encephalopathy-with-continuous-triphasic-waves-in-electroencephalogram
#19
Mihir Parekh, Gopal Krishna Dash, Isthiaque Ahamed
A 74-year-old man with peripheral neuropathy due to diabetes presented with deliberate ingestion of 450 mg of pregabalin (PBG) over a period of 8 hours followed by altered mental status. A bedside electroencephalogram was performed to rule out nonconvulsive status epilepticus, which showed continuous triphasic waves (TWs) with slow background activity. He recovered after 48 hours of stopping PBG, and his repeat electroencephalogram after 72 hours did not show any TWs. We present a rare case of PBG-induced TWs thereby highlighting the extent of the etiologic spectrum of TWs and discussing the literature related to this association...
September 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28857772/a-randomized-double-blind-placebo-controlled-phase-iii-trial-of-selegiline-monotherapy-for-early-parkinson-disease
#20
Yoshikuni Mizuno, Nobutaka Hattori, Tomoyoshi Kondo, Masahiro Nomoto, Hideki Origasa, Ryosuke Takahashi, Mitsutoshi Yamamoto, Nobuo Yanagisawa
BACKGROUND: In Japan, selegiline has been approved for combination therapy with levodopa for Parkinson disease (PD). We conducted a trial of selegiline monotherapy for early PD. METHODS: In this 12-week controlled phase III trial, a total of 292 subjects were randomized to receive placebo (n = 146) (full analysis set 140) or selegiline (n = 146) (full analysis set 139). The primary outcome measure was the change in the Unified Parkinson Disease Rating Scale part I + II + III total score from baseline to the final visit...
September 2017: Clinical Neuropharmacology
journal
journal
26752
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"